

Please amend the claims as follows:

1-28. (Cancelled without prejudice)

29. (Amended) A method of inducing activation of dendritic cells comprising administering a composition to a mammal comprising a polynucleotide or derivative thereof and at least one non-modified polyoxyethylene-polyoxypropylene block copolymer, thereby activating dendritic cells.

30. (Amended) The method of claim [[30]] 29 wherein the block copolymers comprise at least PLURONIC F127 and L61.

31. (Original) The method of claim 30 wherein the block copolymer is present in amounts insufficient for gel formation.

32. (Amended) A method of inducing activation of dendritic cells comprising administering a composition to a mammal comprising a polynucleotide or derivative thereof and at least one non-modified polyoxyethylene-polyoxypropylene block copolymer, wherein the composition forms a molecular solution or colloidal dispersion, thereby activating dendritic cells.

33. (Original) The method of claim 32 wherein the block copolymers are PLURONIC F127 and L61.

34. (Amended) A method of increasing [[the]] an immune response [[of an animal]] comprising administering [[the]] a composition comprising a polynucleotide, viral vector, or polynucleotide derivative thereof and at least one non-modified polyoxyethylene-polyoxypropylene block copolymer [[according to claim 1]] to a mammal, thereby inducing an immune response.

35. (Original) The method of claim 34 wherein the block copolymers comprise at least PLURONIC F127 and L61.

36. (Original) The method of claim 34 wherein the composition is administered orally, topically, rectally, vaginally, parenterally, intramuscularly, intradermally, subcutaneously, intraperitoneally, or intravenously.

37. (Amended) A method of increasing ~~[[the]]~~ an immune response ~~[[of an animal]]~~ comprising intramuscularly administering ~~[[the]]~~ a composition comprising a polynucleotide, viral vector, or polynucleotide derivative thereof and at least one non-modified polyoxyethylene-polyoxypropylene block copolymer ~~[[according to claim 1]]~~ to a mammal, thereby increasing an immune response.

38. (Original) The method of claim 37 wherein the block copolymers comprise at least PLURONIC F127 and L61.

39. (Original) The method of claim 37 wherein said composition is administered to at least one of smooth, skeletal, and cardiac muscles.

40. (Amended) A method of increasing ~~[[the]]~~ an immune response ~~[[of an animal]]~~ comprising intradermally administering ~~[[the]]~~ a composition comprising a polynucleotide, viral vector, or polynucleotide derivative thereof and at least one non-modified polyoxyethylene-polyoxypropylene block copolymer ~~[[according to claim 1]]~~ to a mammal, thereby increasing an immune response.

41-69. (Cancelled without prejudice)

70. (Amended) A method of inducing the activation of dendritic cells comprising administering a composition to a mammal comprising at least one non-modified polyoxyethylene-polyoxypropylene block copolymer ~~[[,]]~~ and a polynucleotide or derivative thereof, wherein the block copolymer is present in amounts insufficient for gel formation.

71. (Original) The method of claim 70 wherein the block copolymers comprise at least PLURONIC F127 and L61.

72. (Amended) A method of inducing activation of dendritic cells comprising administering a composition to a mammal comprising at least one non-modified polyoxyethylene-polyoxypropylene block copolymer [[,]] and a polynucleotide or derivative thereof, wherein the composition forms a molecular solution or colloidal dispersion.

73. (Original) The method of claim 72 wherein the block copolymers are PLURONIC F127 and L61.

74. (Amended) A method of increasing [[the]] an immune response [[of an animal]] comprising administering the composition according to claim 72 to a mammal.

75. (Original) The method of claim 72 wherein the composition is administered orally, topically, rectally, vaginally, parenterally, intramuscularly, intradermally, subcutaneously, intraperitoneally, or intravenously.

76. (Original) The method of claim 72 wherein said composition is administered to at least one of smooth, skeletal, and cardiac muscles.

77. (Amended) A method of improving the immune response of [[an animal]] a mammal comprising intradermally administering the composition according to claim 34.

* * *